Latest

UCLPartners is working with Punto Health and NHS partners on two NIHR-funded innovation trials that aim to reshape how mild cognitive impairment (MCI) and dementia are detected and supported across NHS services.

We are proud to be partnering with Alzheimer's Society, the UK’s leading dementia charity, to support innovators developing new solutions for people affected by dementia, helping them to better understand and navigate the health and care system. 

Dr Arup Nath, Commercial Director, shares how we are working with healthcare providers and industry to tackle the challenges in the Alzheimer’s disease care pathway head-on to make a meaningful difference for everyone affected.

As new disease-modifying therapies for Alzheimer's emerge, there’s a crucial opportunity to enhance dementia diagnosis, treatment and care. We reflect on insights from a recent roundtable bringing together experts from across the dementia pathway.

The National Institute for Health and Care Excellence’s (NICE) technology appraisal process for two new Disease Modifying Therapies (DMTs) for Alzheimer’s Disease is due to conclude in the summer of 2024. These emerging therapies represent a potentially seismic shift in the care of patients with dementia. But how do we prepare services and ensure equal access?